Regulatory Pathways
Regulatory approval, scheduling, special access, and country-level rules that decide whether a therapy can be used medically.
Regulatory approval turns evidence into a legal treatment option. It does not decide who pays, how services are delivered, or how quickly patients can reach care.
Psychedelic therapies add extra regulatory questions: controlled-substance handling, site rules, psychological support, safety monitoring, and the boundary between research, special access, and routine care.
Use this section to compare the formal routes: FDA and EMA pathways, national rules, compassionate use, authorised-prescriber models, and state-level service frameworks.
Further reading
Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use
regulation source relevant to regulatory pathways.
European Parliament and Council of the European Union | 16 Apr 2014 | EU | Regulation | Reviewed 17 Apr 2026
Council Directive 89/105/EEC (Transparency Directive for medicines pricing and reimbursement)
regulation source relevant to regulatory pathways.
Council of the European Communities | 21 Dec 1988 | EU | Regulation | Reviewed 17 Apr 2026
Guideline on clinical investigation of medicinal products in the treatment of depression (Rev.3)
guidance source relevant to regulatory pathways.
European Medicines Agency (EMA) | 15 Sept 2023 | EU | Guidance | Reviewed 17 Apr 2026
CHMP summary of positive opinion for Spravato (EMA/557804/2019)
Regulatory opinion document relevant to authorisation-to-access pathway interpretation.
European Medicines Agency (EMA) | 17 Oct 2019 | EU | Guidance | Reviewed 17 Apr 2026
Notice to stakeholders: Requests to the Special Access Program involving psychedelic-assisted psychotherapy
guidance source relevant to regulatory pathways.
Health Canada | 27 Feb 2023 | Canada | Guidance | Reviewed 17 Apr 2026
Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists
framework source relevant to regulatory pathways.
Therapeutic Goods Administration (Australia) | 3 Feb 2023 | Australia | Framework | Reviewed 17 Apr 2026
FDA approves new nasal spray medication for treatment-resistant depression
framework source relevant to regulatory pathways.
US Food and Drug Administration (FDA) | 5 Mar 2019 | US | Framework | Reviewed 17 Apr 2026